Lucas Chun Wah Fong

Lucas Chun Wah Fong

Auto-generated profile, based on publicly available information

Lucas Chun Wah Fong

Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 July 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
LFLucas Chun Wah Fong
Lucas Chun Wah Fong
TFThomas J. Ford
Thomas J. Ford
BCBruno R. da Costa
Bruno R. da Costa
PJPeter Jüni
Peter Jüni
CBColin Berry
Colin Berry
Background: Loss to follow‐up ( LTFU ) is common in randomized controlled trials. However, its potential impact on primary outcomes from cardiovascular randomized controlled trials is not known. Methods and Results: We conducted a prospective systematic review ( PROSPERO : CRD 42019121959) for randomized controlled trials published in 8 leading journals over 5 years from January 2014 to December 2018. Extent, reporting, and handling of LTFU data were recorded, and the proportion of a trial's primary outcome results that lose statistical significance was calculated after making plausible assumptions for the intervention and control arms. These assumptions could drive differential treatment effects between the groups considering relative event incidence between LTFU participants and those included in the primary outcome. We identified 117 randomized controlled trials of which 91 (78%) trials reported LTFU , 23 (20%) reported no LTFU , and 3 (3%) trials did not report on whether LTFU occurred. The median percentage of study participants lost to follow‐up was 2% (interquartile range, 0.33%–5.3%). Only 10 trials (9%) had a low cluster of risk factors for impairment in trial quality. The percentage of trials losing statistical significance varied from 2% when the relative event incidence for LTFU between the randomized groups was 1 for the intervention arm and 1.5 for the control arm to 16% when the relative event incidence was 3 for the intervention arm and 1 for the control arm. Conclusions: Almost 1 in 6 (16%) cardiovascular randomized trials published in leading journals may have a change in the primary outcome if plausible assumptions are made about differential event rates of participants lost to follow up. There is scope for improvement arising from LTFU in randomized trials in cardiovascular medicine. Registration: URL : https://www.crd.york.ac.uk/prospero ; Unique identifier: CRD 42019121959.

5 November 2021 in Cardiology
Verified
Journal Article
Open access
PDF file
LFLucas Chun Wah Fong
Lucas Chun Wah Fong
NLNicholas Ho Cheung Lee
Nicholas Ho Cheung Lee
AYAndrew T. Yan
Andrew T. Yan
MNMing Yen Ng
Ming Yen Ng
Introduction: There have been inconsistent data on the direct comparison of prasugrel and ticagrelor. This meta-analysis was conducted to summarize the current available evidence. Methods: We performed a meta-analysis (PROSPERO-registered CRD42020166810) of randomized trials up to February 2020 that compared prasugrel and ticagrelor in acute coronary syndrome with respect to the composite endpoint of myocardial infarction (MI), stroke, or cardiovascular death and secondary endpoints including MI, stroke, cardiovascular death, major bleeding (Bleeding Academic Research Consortium (BARC) type 2 or above), stent thrombosis, all-cause death, and other safety outcomes. Results: Of the 11 eligible RCTs with 6,098 patients randomized to prasugrel (n = 3,050) or ticagrelor (n = 3,048), 180 and 207 had the composite endpoint events in the prasugrel arm and the ticagrelor arm, respectively, over a weighted mean follow-up period of 11 ± 2 months. Compared with prasugrel, the ticagrelor group had similar risk in the primary composite endpoint (risk ratio [RR] = 1.17; 95% CI = 0.96–1.42; p = 0.12, I2 = 0%). Compared to prasugrel, there was no significant difference associated with the ticagrelor groups with respect to stroke (RR = 1.05; 95% CI = 0.66–1.67; p = 0.84, I2 = 0%), cardiovascular death (RR = 1.01; 95% CI = 0.75–1.36; p = 0.95, I2 = 0%), BARC type 2 or above bleeding (RR = 1.16; 95% CI = 0.89–1.52; p = 0.26, I2 = 0%), stent thrombosis (RR = 1.58; 95% CI = 0.90–2.76; p = 0.11, I2 = 0%), and all-cause death (RR = 1.10; 95% CI = 0.86–1.43; p = 0.45, I2 = 0%) except MI (RR = 1.38; 95% CI = 1.05–1.81; p = 0.02, I2 = 0%) Conclusion: Compared with prasugrel, ticagrelor did not reduce the primary composite endpoint of MI, stroke, and cardiovascular death at a weighted mean follow-up of 11 months. There was no significant difference between the secondary outcomes except MI.

1 January 2021 in Cardiovascular Imaging Asia
Verified
Journal Article
Open access
PDF file
MNMing Yen Ng
Ming Yen Ng
HTHok Shing Tang
Hok Shing Tang
LFLucas Chun Wah Fong
Lucas Chun Wah Fong
VCVictor Chan
Victor Chan
RSRoxy Senior
Roxy Senior
DPDudley John Pennell
Dudley John Pennell
Ng MY, et al. Cardiovasc Imaging Asia. 2021 Jul;5(3):83-93. https://doi.org/10.22468/cvia.2021.00129